NASDAQ:MEDP

Medpace Stock Forecast, Price & News

$190.76
+5.80 (+3.14 %)
(As of 09/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$184.19
$191.25
50-Day Range
$170.18
$195.17
52-Week Range
$105.48
$198.03
Volume146,109 shs
Average Volume188,481 shs
Market Capitalization$6.83 billion
P/E Ratio41.11
Dividend YieldN/A
Beta1.33
30 days | 90 days | 365 days | Advanced Chart
Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.


Medpace logo

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.26 out of 5 stars

Medical Sector

287th out of 1,352 stocks

Commercial Physical Research Industry

3rd out of 26 stocks

Analyst Opinion: 1.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Medpace (NASDAQ:MEDP) Frequently Asked Questions

Is Medpace a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Medpace stock.
View analyst ratings for Medpace
or view top-rated stocks.

What stocks does MarketBeat like better than Medpace?

Wall Street analysts have given Medpace a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medpace wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, October 25th 2021.
View our earnings forecast for Medpace
.

How can I listen to Medpace's earnings call?

Medpace will be holding an earnings conference call on Tuesday, October 26th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5177474".

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) released its earnings results on Sunday, July, 25th. The company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.99 by $0.07. The company had revenue of $278.29 million for the quarter, compared to analyst estimates of $271.20 million. Medpace had a trailing twelve-month return on equity of 21.74% and a net margin of 17.07%.
View Medpace's earnings history
.

How has Medpace's stock price been impacted by COVID-19?

Medpace's stock was trading at $83.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEDP stock has increased by 128.1% and is now trading at $190.76.
View which stocks have been most impacted by COVID-19
.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2021 earnings guidance on Monday, August, 2nd. The company provided earnings per share (EPS) guidance of $4.310-$4.500 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.380. The company issued revenue guidance of $1.11 billion-$1.15 billion, compared to the consensus revenue estimate of $1.13 billion.

What price target have analysts set for MEDP?

3 equities research analysts have issued 1 year target prices for Medpace's shares. Their forecasts range from $167.90 to $205.00. On average, they anticipate Medpace's share price to reach $190.97 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts' price targets for Medpace
or view top-rated stocks among Wall Street analysts.

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • August James Troendle, Chairman & Chief Executive Officer
  • Jesse J. Geiger, President
  • Susan E. Burwig, Executive Vice President-Operations
  • Kevin M. Brady, Chief Financial Officer & Treasurer
  • Daniel O’Leary, Senior Vice President-Medical Department

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace CEO August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among Medpace's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Square (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.37%), Vanguard Group Inc. (9.01%), Wasatch Advisors Inc. (6.84%), Invesco Ltd. (2.59%), State Street Corp (2.37%) and Price T Rowe Associates Inc. MD (1.96%). Company insiders that own Medpace stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Peter J O'malley, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends for Medpace
.

Which institutional investors are selling Medpace stock?

MEDP stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., BlackRock Inc., Eagle Asset Management Inc., FMR LLC, abrdn plc, Jupiter Asset Management Ltd., Vanguard Group Inc., and Bernzott Capital Advisors. Company insiders that have sold Medpace company stock in the last year include Ashley M Keating, August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Stephen P Ewald, Susan E Burwig, and Tom C King.
View insider buying and selling activity for Medpace
or view top insider-selling stocks.

Which institutional investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including Echo Street Capital Management LLC, Vulcan Value Partners LLC, Goldman Sachs Group Inc., American Capital Management Inc., Dimensional Fund Advisors LP, Amundi, Epoch Investment Partners Inc., and Monarch Partners Asset Management LLC. Company insiders that have bought Medpace stock in the last two years include Peter J O'malley, and Wedbush Securities Inc.
View insider buying and selling activity for Medpace
or or view top insider-buying stocks.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $190.76.

How much money does Medpace make?

Medpace has a market capitalization of $6.83 billion and generates $925.92 million in revenue each year. The company earns $145.38 million in net income (profit) each year or $4.00 on an earnings per share basis.

How many employees does Medpace have?

Medpace employs 3,600 workers across the globe.

What is Medpace's official website?

The official website for Medpace is www.medpace.com.

Where are Medpace's headquarters?

Medpace is headquartered at 5375 MEDPACE WAY, CINCINNATI OH, 45227.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at (513) 579-9911 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.